Oxcarbazepine


Concise Prescribing Info
Indications/Uses
Partial seizures.
Dosage/Direction for Use
Adult: PO As monotherapy or adjunctive therapy: Initial: 600 mg/day in 2 divided doses, may increase if necessary in max increments of 600 mg/day at wkly interval. Maintenance: 600-1,200 mg/day or up to 2,400 mg/day in adjunctive therapy or in refractory patients switched from other antiepileptics.
Administration
May be taken with or without food.
Contraindications
Lactation.
Special Precautions
Patient carrying HLA-B*15:02 allele. Avoid abrupt withdrawal. Severe renal and hepatic impairment. Pregnancy. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor seizure frequency, serum Na, symptoms of CNS depression, hypersensitivity reactions, serum levels of concomitant antiepileptic drugs during titration; periodic thyroid function test and CBC.
Adverse Reactions
Hyponatraemia; suicidal behaviour or ideation; neuropsychiatric effects (e.g. impaired cognitive or psychomotor performance, somnolence or fatigue, incoordination); dizziness, somnolence, diplopia, fatigue, nausea, vomiting, ataxia, abnormal vision, abdominal pain, tremor, dyspepsia, abnormal gait, hypothyroidism. Rarely, pancytopenia, agranulocytosis, leucopenia.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis; anaphylaxis, angioedema; Drug Reaction w/ Eosinophilia and Systemic Symptoms (DRESS).
Drug Interactions
May increase plasma concentrations of other anticonvulsants (e.g. phenobarbital, phenytoin). May decrease plasma concentrations of OC and Ca channel blockers. Decreased plasma concentrations w/ potent inducers of CYP isoenzymes (e.g. carbamazepine, phenytoin, phenobarbital).
CIMS Class
ATC Classification
N03AF02 - oxcarbazepine ; Belongs to the class of carboxamide derivatives antiepileptic.
Disclaimer: This information is independently developed by CIMS based on oxcarbazepine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in